US OptionsDetailed Quotes
MGNX250117P6000
- 0.00
- 0.000.00%
15min DelayClose Jan 7 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest6.00Strike Price0.00Turnover221.46%IV-75.95%PremiumJan 17, 2025Expiry Date2.59Intrinsic Value100Multiplier9DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9184Delta0.1262Gamma1.30Leverage Ratio-0.0087Theta-0.0011Rho-1.19Eff Leverage0.0008Vega
Macrogenics Stock Discussion
Sign in to post a comment
$Macrogenics (MGNX.US)$ Financial Performance:
MacroGenics reported a significant increase in Q2 2024 revenue of $110.7 million, compared to $10.4 million in the same quarter the previous year.
Net income for the quarter was $56.3 million, significantly higher than the $17.6 million recorded in Q3 2023.
The financial improvements were largely due to a $100 million milestone payment from Incyte, a...
MacroGenics reported a significant increase in Q2 2024 revenue of $110.7 million, compared to $10.4 million in the same quarter the previous year.
Net income for the quarter was $56.3 million, significantly higher than the $17.6 million recorded in Q3 2023.
The financial improvements were largely due to a $100 million milestone payment from Incyte, a...
8
$Macrogenics (MGNX.US)$ Any that are interested! I advise reading Doc 2 in that new 8K! Could be a very interesting upcoming catalyst before EOY! Hehehe
1
$Macrogenics (MGNX.US)$ Reuters· just
MacroGenics Q3 Net Income USD 56.3 Million Vs. IBES Estimate USD 11.2 Million
MacroGenics Q3 Net Income USD 56.3 Million Vs. IBES Estimate USD 11.2 Million
1
$Macrogenics (MGNX.US)$
Positive
▪️Revenue increased significantly to $110.7M from $10.4M YoY
▪️Net income grew to $56.3M from $17.6M YoY
▪️Strong cash position of $200.4M
▪️Secured $100M milestone payment from Incyte
▪️Pending MARGENZA sale for $40M upfront plus up to $35M in milestones
Negative
▪️R&D expenses increased to $40.5M from $30.1M YoY
▪️SG&A expenses rose to $14.1M from $12.4M YoY
▪️Paused development efforts in alternative tumor types for vobra duo
Positive
▪️Revenue increased significantly to $110.7M from $10.4M YoY
▪️Net income grew to $56.3M from $17.6M YoY
▪️Strong cash position of $200.4M
▪️Secured $100M milestone payment from Incyte
▪️Pending MARGENZA sale for $40M upfront plus up to $35M in milestones
Negative
▪️R&D expenses increased to $40.5M from $30.1M YoY
▪️SG&A expenses rose to $14.1M from $12.4M YoY
▪️Paused development efforts in alternative tumor types for vobra duo
1
$Macrogenics (MGNX.US)$
22/10/2024 - 19:30
ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)-- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain ma...
22/10/2024 - 19:30
ROCKVILLE, Md. & DEERFIELD, Ill.--(BUSINESS WIRE)-- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, and TerSera Therapeutics LLC, a privately-held biopharmaceutical company with a focus in oncology and non-opioid pain ma...
$Macrogenics (MGNX.US)$ get up and let's go..
$Macrogenics (MGNX.US)$
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) presented updated efficacy and safety results from the TAMARACK Phase 2 study of vobramitamab duocarmazine(vobra duo) for metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024.
Key findings include:
▪️6-month radiographic progression-free survival (rPFS) rate: 69% for 2.0 mg...
$Macrogenics (MGNX.US)$
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...
MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024
MacroGenics (NASDAQ: MGNX) announced a poster presentation of Phase 2 data for vobramitamab duocarmazine in metastatic castration-resistant prostate cancer (mCRPC) at the ESMO Congress 2024. The TAMARACK trial results will be presented on September 15, 2024, featuring updated safety and efficacy data, including the primary endpoint of 6-month radiographic progression-free survival (rPFS).
Th...
2
$Macrogenics (MGNX.US)$
f@#$%^&* up
f@#$%^&* up
No comment yet
Lnova :
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Lnova : good job $Macrogenics (MGNX.US)$![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Trytosaveabit OP Lnova : Plus expected to receive another 40 million payment before EOY
Lnova Trytosaveabit OP :![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
wow 
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
watching ![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
Lnova : The turnover looks 4x the volume. It is shorted ?![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
View more comments...